$PLRX Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Sol...

dough· @semodough · X·2026-04-19 01:33· 2026-04-19Score60

Body

$PLRX Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 #AACR26 Annual Meeting - Pliant Therapeutics, Inc.

Heat 3 · 3 likes · 0 replies · 0 reposts

Conference abstracts

CT002NCT06270706matched by 代号 PLN-101095

First-in-human phase I study of PLN-101095, a first-in-class dual αvβ8/αvβ1integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI)

Timothy A. Yap, Andrae Vandross, Jenny Amaya-Amaya, Chris N. Barnes, Shuguang Ma, Martin Decaris, Keithryn Nicolas, Alexander Spira, Jacqueline Brown, Patricia LoRusso, Manish R. Sharma

Read the abstract →

Source: dough · x.com